GUANGZHOU NOVAKEN
GenericsGUANGZHOU NOVAKEN is a generic drug manufacturer focused on Infectious Disease, Cardiovascular, Gastroenterology.
GUANGZHOU NOVAKEN's Key Drugs
GUANGZHOU NOVAKEN's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
GUANGZHOU NOVAKEN's Recent FDA Approvals
New NDA/BLA approvals for GUANGZHOU NOVAKEN over the last two years — novel drugs only, excluding generics and label supplements.
GUANGZHOU NOVAKEN's Therapeutic Areas
GUANGZHOU NOVAKEN's approved drugs and pipeline span 4 therapeutic areas, led by Infectious Disease and Cardiovascular. Weighted by commercial stage — approved drugs count most, then late-stage trials.
GUANGZHOU NOVAKEN's Top Competitors
GUANGZHOU NOVAKEN's closest competitors by therapeutic-area and drug-target overlap include WARNER CHILCOTT, Bristol-Myers Squibb, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
GUANGZHOU NOVAKEN Pipeline Snapshot
GUANGZHOU NOVAKEN has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2020-11-18
- Latest
- 2024-07-17
- Applications
- 2